PMID: 2022407May 1, 1991Paper

Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism

S A GriffinA F Lever


Angiotensin II, when given in low doses, raises blood pressure slowly. When tested in vitro on vascular smooth muscle cells, it has mitogenic and trophic effects; it is not known if it has these effects in vivo. Our purpose was to determine whether vascular hypertrophy develops during slow pressor infusion of angiotensin II and, if so, whether it is pressure induced. Three experiments were done in rats infused subcutaneously with angiotensin II (200 ng/kg/min) by minipump for 10-12 days. Experiment 1: Angiotensin II gradually raised systolic blood pressure (measured in the tail) from 143 +/- 2 to 208 +/- 8 mm Hg (mean +/- SEM), significantly suppressing plasma renin and increasing threefold (NS) plasma angiotensin II. There was no loss of peptide in the pump infusate when tested at the end of the experiment. Experiment 2: In the perfused mesenteric circulation, vasoconstrictor responses to norepinephrine, vasopressin, and KCl were enhanced in rats given a slow pressor infusion of angiotensin II, but sensitivity of responses was not altered. This combination of changes suggests that vascular hypertrophy develops during slow pressor infusion of angiotensin II. Experiment 3: Vessel myography was done after angiotensin II infusion ...Continue Reading


Jun 1, 1975·Clinical Science and Molecular Medicine. Supplement·B Folkow
Dec 1, 1988·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·F LyallE J Cragoe
Apr 1, 1987·Hypertension·R C VariR H Freeman
Apr 1, 1987·Hypertension·G D FinkM L Mangiapane
Apr 1, 1985·Canadian Journal of Physiology and Pharmacology·R M Lee, J S Smeda
Jun 7, 1985·European Journal of Pharmacology·A K GroverE E Daniel
Apr 1, 1985·Clinical Science·J J Morton, D J Webb
Jan 1, 1985·Clinical and Experimental Hypertension. Part A, Theory and Practice·P A SchlegelH R Brunner
Nov 1, 1984·The Biochemical Journal·J McQueenP F Semple
Jan 1, 1984·General Pharmacology·V L Peres-Polon, F M Corrêa
Dec 1, 1984·Journal of Hypertension·B G ZimmermanP C Wong
Jan 1, 1983·The American Journal of Physiology·A J BrownA F Lever
Feb 14, 1980·Clinica Chimica Acta; International Journal of Clinical Chemistry·J A MillarM Tree
May 1, 1981·The Journal of Cell Biology·J H Chamley-CampbellR Ross
Oct 1, 1981·Experimental and Molecular Pathology·M Campbell-Boswell, A L Robertson

❮ Previous
Next ❯


Sep 10, 1998·Journal of Cellular Physiology·L A Quinn, W D McCumbee
Jul 9, 2005·European Journal of Applied Physiology·Muzaffer ColakogluMetin Sayin
Aug 3, 2005·Cellular and Molecular Neurobiology·Juan M Saavedra
Jul 11, 1992·Journal of the American College of Cardiology·K T WeberC V Leier
Jan 1, 1994·Progress in Growth Factor Research·W R Huckle, H S Earp
Oct 1, 1995·Journal of Diabetes and Its Complications·T J AllenM E Cooper
Nov 4, 2000·Regulatory Peptides·J Haendeler, B C Berk
Oct 18, 2000·Regulatory Peptides·K M Schmidt-OttM I Phillips
Aug 6, 1998·Cellular Signalling·R H Weiss
Aug 1, 1996·Trends in Cardiovascular Medicine·P DelafontaineJ Du
Mar 21, 2002·Clinical and Experimental Pharmacology & Physiology·S FicaiB Jover
Mar 21, 2002·Clinical and Experimental Pharmacology & Physiology·T Morgan
Mar 21, 2002·Clinical and Experimental Pharmacology & Physiology·A EdgleyW Anderson
Jun 20, 1996·The New England Journal of Medicine·T L GoodfriendK J Catt
Oct 26, 1999·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·K MaedaK A Hossmann
Jan 1, 1996·Journal of Cardiovascular Pharmacology·B Waeber, H R Brunner
Jun 1, 1997·Journal of Cardiovascular Pharmacology·F R StassenJ G De Mey
Jul 1, 1997·Journal of Cardiovascular Pharmacology·J S LiE L Schiffrin
Oct 22, 1998·Journal of Cardiovascular Pharmacology·A HolmgrenL Edvinsson
Jan 16, 1999·Journal of Cardiovascular Pharmacology·A L Le RoyD Benzoni
Dec 18, 2001·Journal of Cardiovascular Pharmacology·John P CollisterJohn W Osborn
Jul 27, 2005·Journal of Cardiovascular Pharmacology·John P Collister, John W Osborn
Apr 5, 2013·Clinical and Experimental Pharmacology & Physiology·Duncan J Campbell
May 1, 1992·Clinical and Experimental Pharmacology & Physiology·K JandeleitM E Cooper
May 1, 1993·Clinical and Experimental Pharmacology & Physiology·K M SummersM J West
Aug 1, 1996·Clinical and Experimental Pharmacology & Physiology·M J Mulvany
Jul 9, 2004·Clinical and Experimental Pharmacology & Physiology·Jocelyne BlancJean-Luc Elghozi
Oct 2, 2009·Clinical and Experimental Pharmacology & Physiology·Trasida PloyngamJohn P Collister
Jan 1, 1994·British Journal of Pharmacology·A HilditchM J Robertson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.